Generic

May 14, 2019

Price fixing case caps a terrible week for generics

Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.

Price fixing case caps a terrible week for generics

Civica Rx goes where generics companies fear to tread

Pfenex readies to swim upstream with Forteo copycat

Biosimilar knockbacks expose increasing big pharma focus

Private equity cleans up Sanofi’s failed generics foray

Interview – Rani’s pill injector promises much, but is still preclinical

Novartis investors put faith in new chief

Teva investors applaud and staff revolt, as Schultz swings the axe

A determined FDA takes down Teva’s blockbuster

Abbvie sets the date for cash cow slaughter

Is parting such sweet Soriot for Astrazeneca?

Latest Reports

Vantage Pharma, Biotech and Medtech 2018 in Review

Vantage 2019 Preview

Editor's Picks

Asco 2019 – Abstract drop fires the starting gun

Who will capitalise on CAR-T at last? Not big pharma, says Tmunity

Price fixing case caps a terrible week for generics

Astra makes machine learning bet with Benevolent AI deal

Looking back at April’s data digging and analysis